Encouraging that MedAdvisor US revenues went from $7.6M in the...

Encouraging that MedAdvisor US revenues went from $7.6M in the March quarter to $11.2M in June.

Payments to suppliers and employees for MedAdvisor US conversely went down from $14.9M to $13.3M.

It also looks like ROW (Rest Of World, that being AU and UK) payments have also reduced. December quarter was $6.2M, June quarter $4.2M.

Management did state the aim of acquiring Adheris was to return the revenues back to the highs from only a few years ago. And they would have seen some overlap in roles and technology.

If the September quarter can show a further increase from US revenues and also find some further cost savings, then the acquisition, costs to acquire, time to combine both organisations appears to have been positive.

There's 5 for more quarters in cash reserves. If they can gain traction in the UK with ~400 NPA pharmacies and hook a few more US pharma programs, then as @Patient states in the other thread, FY22 might just be the year we see a return to a more reasonable and aspirational market cap and share price.